FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898830599> ?p ?o ?g. }

• W2898830599 endingPage "4234" @default.
• W2898830599 startingPage "4234" @default.
• W2898830599 abstract "Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are hematologic malignancies with poor prognosis for patients who do not respond well to therapy. As current treatment options may be suboptimal for many patients, it is important to better understand the current treatment landscape for DLBCL and FL. Here we provide recent real-world evidence on patient characteristics and treatment patterns in relapsed/refractory (R/R) DLBCL and R/R FL across the United Kingdom (UK), France (FRA), and Germany (DE). Methods: Hematologists and oncologists (N=140) from the UK, FRA, or DE retrospectively identified patients diagnosed with R/R DLBCL or R/R FL who received at least two lines of therapy and had radiographically or clinically measurable disease with at least one target lesion per International Working Group criteria for malignant lymphoma. Descriptive statistics examined patient characteristics and treatment patterns in first-line (1L) and second-line (2L) therapy. Results: Mean (SD) age at initial diagnosis was 59.9 (10.9) years for the aggregate DLBCL patient sample (N=272). DLBCL patients were primarily male (69.1%), distributed across the UK (29.0%), FRA (36.8%), and DE (34.2%), and had various Eastern Cooperative Oncology Group (ECOG) performance statuses at initial diagnosis (0 ECOG 28.7%, 1 ECOG 48.9%, 2 ECOG 14.3%, ≥3 ECOG 5.9%, unknown ECOG 2.2%). Mean (SD) age at initial diagnosis was 61.0 (10.2) years for the aggregate FL patient sample (N=282). FL patients were primarily male (53.9%), distributed across the UK (29.4%), FRA (36.9%), and DE (33.7%), and had various ECOG performance statuses at initial diagnosis (0 ECOG 30.5%, 1 ECOG 50.7%, 2 ECOG 13.5%, ≥3 ECOG 4.2%, unknown ECOG 1.1%). DLCBL and FL patient characteristics by country are presented in Table 1. DLCBL patients in 1L and 2L received combination regimens (93.8% and 82.7%, respectively) or monotherapy regimens (6.2% and 17.3%, respectively). DLCBL patients in 1L received treatment largely consistent with current guidelines, consisting mainly of systemic therapy only (86.8%) and treatment with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP, 68.0%). DLCBL patients in 2L completed multiple therapy cycles (median 3 cycles) and were treated with systemic therapy only (79.4%), systemic therapy and radiation (4.0%), systemic therapy and stem cell transplantation (SCT, 16.2%), or systemic therapy, radiation, and SCT (0.4%). The most common 2L DLCBL regimens were: rituximab, dexamethasone, high-dose cytosine arabinoside, and cisplatin (R-DHAP, 19.5%); bendamustine plus rituximab (12.9%); rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX, 12.5%). FL patients in 1L and 2L received combination regimens (86.5% and 78.4%, respectively) or monotherapy regimens (13.5% and 21.6%, respectively). FL patients in 1L received treatment largely consistent with current guidelines, consisting mainly of systemic therapy only (90.8%) and treatment with R-CHOP (35.1%). FL patients in 2L completed multiple therapy cycles (median 4 cycles) and were treated with systemic therapy only (90.1%), systemic therapy and radiation (2.1%), systemic therapy and SCT (6.0%), or systemic therapy, radiation, and SCT (1.8%). The most common 2L FL regimens were: bendamustine plus rituximab (33.3%); R-CHOP (9.6%); R-DHAP (8.5%). DLCBL and FL 2L treatment patterns by country are presented in Table 2. Conclusion/Summary: Given the rapid evolution of therapies used to treat FL and DLBCL, these findings fill a crucial data gap in real-world evidence on patient characteristics and treatment patterns in R/R DLCBL and R/R FL in the UK, FRA, and DE. There is an unmet need in DLBCL and FL. As novel treatments for patients with DLBCL and FL are currently in development, it is important to better understand the patients being treated for these conditions and the current treatment landscape. Disclosures Galaznik: Takeda Pharmaceuticals International Co.: Employment. Way:Seattle Genetics: Research Funding; Kantar Health: Employment." @default.
• W2898830599 created "2018-11-09" @default.
• W2898830599 creator A5028607002 @default.
• W2898830599 creator A5079590292 @default.
• W2898830599 date "2018-11-29" @default.
• W2898830599 modified "2023-10-01" @default.
• W2898830599 title "Patient Characteristics and Treatment Patterns in the First-Line and Second-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the United Kingdom, France, and Germany" @default.
• W2898830599 doi "https://doi.org/10.1182/blood-2018-99-112617" @default.
• W2898830599 hasPublicationYear "2018" @default.
• W2898830599 type Work @default.
• W2898830599 sameAs 2898830599 @default.
• W2898830599 citedByCount "1" @default.
• W2898830599 countsByYear W28988305992020 @default.
• W2898830599 crossrefType "journal-article" @default.
• W2898830599 hasAuthorship W2898830599A5028607002 @default.
• W2898830599 hasAuthorship W2898830599A5079590292 @default.
• W2898830599 hasBestOaLocation W28988305991 @default.
• W2898830599 hasConcept C126322002 @default.
• W2898830599 hasConcept C143998085 @default.
• W2898830599 hasConcept C2777058707 @default.
• W2898830599 hasConcept C2778559949 @default.
• W2898830599 hasConcept C2779338263 @default.
• W2898830599 hasConcept C2780653079 @default.
• W2898830599 hasConcept C2781442060 @default.
• W2898830599 hasConcept C71924100 @default.
• W2898830599 hasConceptScore W2898830599C126322002 @default.
• W2898830599 hasConceptScore W2898830599C143998085 @default.
• W2898830599 hasConceptScore W2898830599C2777058707 @default.
• W2898830599 hasConceptScore W2898830599C2778559949 @default.
• W2898830599 hasConceptScore W2898830599C2779338263 @default.
• W2898830599 hasConceptScore W2898830599C2780653079 @default.
• W2898830599 hasConceptScore W2898830599C2781442060 @default.
• W2898830599 hasConceptScore W2898830599C71924100 @default.
• W2898830599 hasIssue "Supplement 1" @default.
• W2898830599 hasLocation W28988305991 @default.
• W2898830599 hasOpenAccess W2898830599 @default.
• W2898830599 hasPrimaryLocation W28988305991 @default.
• W2898830599 hasRelatedWork W1594335059 @default.
• W2898830599 hasRelatedWork W1972710872 @default.
• W2898830599 hasRelatedWork W2013338985 @default.
• W2898830599 hasRelatedWork W2020184844 @default.
• W2898830599 hasRelatedWork W2087366892 @default.
• W2898830599 hasRelatedWork W2102241654 @default.
• W2898830599 hasRelatedWork W2883201369 @default.
• W2898830599 hasRelatedWork W2922082795 @default.
• W2898830599 hasRelatedWork W2979695321 @default.
• W2898830599 hasRelatedWork W2980742945 @default.
• W2898830599 hasVolume "132" @default.
• W2898830599 isParatext "false" @default.
• W2898830599 isRetracted "false" @default.
• W2898830599 magId "2898830599" @default.
• W2898830599 workType "article" @default.